aTYR PHARMA INC (LIFE) [Rocket]

Overview

aTYR PHARMA INC (LIFE)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/10/2023	S-8	Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/09/2023	8-K	Quarterly results
08/01/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
05/19/2023	4	Zaknoen Sara (Director) has filed a Form 4 on aTYR PHARMA INC
05/19/2023	4	SCHIMMEL PAUL (Director) has filed a Form 4 on aTYR PHARMA INC
05/19/2023	4	Lucas Svetlana (Director) has filed a Form 4 on aTYR PHARMA INC

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
Revenues	10.4	10.4	0.0	23.3	10.5	0.4	0.0	0.0
Revenue growth		-55.4%	-100.0%		2377.5%
Cost of goods sold	0.0	56.8	0.0	34.0	0.0	0.0	0.0	0.0
Gross profit	10.4	-46.4	0.0	-10.8	10.5	0.4	0.0	0.0
Gross margin	100.0%	-446.8%		-46.2%	100.0%	100.0%
Selling, general and administrative	56.8		34.0		26.4
Research and development						14.0	20.4	30.1
General and administrative		14.0		10.8		9.4	12.4	17.1
EBIT	-44.3	-46.4	-33.5	-34.0	-16.5	-23.0	-32.8	-47.1
EBIT margin	-426.3%	-446.8%		-146.2%	-158.3%	-5445.0%
Pre-tax income	-45.3	-45.3	-33.8	-33.8	-16.2	-23.8	-34.5	-48.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-45.3	-45.3	-33.8	-33.8	-16.2	-23.6	-34.5	-48.2
Net margin	-436.5%	-436.5%		-145.2%	-155.2%	-5593.1%

Diluted EPS	($1.60)	($1.60)	($1.77)	($1.77)	($1.77)	($7.03)	($16.11)	($26.13)
Shares outstanding (diluted)	28.4	28.4	19.1	19.1	9.2	3.4	2.1	1.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.